Open Access肝硬化合并糖尿病患者的SGLT2抑制剂:一项三级中心队列研究和对门静脉高压症潜在治疗靶点的认识
Author(s) -
Saffo Saad,
GarciaTsao Guadalupe,
Taddei Tamar
Publication year - 2021
Publication title -
journal of diabetes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.949
H-Index - 43
eISSN - 1753-0407
pISSN - 1753-0393
DOI - 10.1111/1753-0407.13136
Subject(s) - medicine , diabetes mellitus , cirrhosis , portal hypertension , center (category theory) , cohort , cohort study , endocrinology , chemistry , crystallography
Highlights Sodium glucose cotransporter 2 (SGLT2) inhibitors have favorable pleiotropic effects in patients with diabetes mellitus and cardiovascular or renal disease. The benefits of SGLT2 inhibitors may extend to portal hypertension, but they have not been formally evaluated in patients with cirrhosis. Our study is the first to provide clinical data for SGLT2 inhibitors in a cohort of patients with cirrhosis, and our findings support ongoing evaluation in the form of a clinical trial.